# Neoadjuvant Chemotherapy of Primary Breast Cancer With Epirubicin/Docetaxel and Carboplatin/Docetaxel

> **NCT00527449** · PHASE2 · COMPLETED · sponsor: **Klinikum Weissenfels** · enrollment: 50 (actual)

## Conditions studied

- Primary Breast Cancer

## Interventions

- **DRUG:** Epirubicin, Carboplatin, Docetaxel

## Key facts

- **NCT ID:** NCT00527449
- **Lead sponsor:** Klinikum Weissenfels
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2010-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00527449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00527449, "Neoadjuvant Chemotherapy of Primary Breast Cancer With Epirubicin/Docetaxel and Carboplatin/Docetaxel". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00527449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*